Gwenn Hansen Sells 1,452 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $25.47, for a total value of $36,982.44. Following the sale, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,985,771.69. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total transaction of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $25.82 on Thursday. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $28.23. The company has a market cap of $2.68 billion, a P/E ratio of -7.48 and a beta of 1.80. The firm has a 50 day simple moving average of $24.79 and a two-hundred day simple moving average of $19.21.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The business had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on NRIX. Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Wells Fargo & Company downgraded shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price target for the stock from $28.00 to $25.00 in a report on Monday, June 8th. HC Wainwright increased their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Oppenheimer started coverage on Nurix Therapeutics in a research report on Monday, June 29th. They set an “outperform” rating and a $28.00 price objective on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.21.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at about $212,769,000. General Atlantic L.P. acquired a new position in shares of Nurix Therapeutics in the fourth quarter worth approximately $92,899,000. Morgan Stanley lifted its stake in shares of Nurix Therapeutics by 115.9% in the fourth quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after acquiring an additional 2,620,323 shares during the period. Rubric Capital Management LP bought a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $46,930,000. Finally, Braidwell LP bought a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $41,428,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.